Oncology Institute (NASDAQ: TOI) releases Q3 2025 results

Rhea-AI Filing Summary

The Oncology Institute, Inc. filed a current report stating that it issued a press release announcing its financial results for the three months ended September 30, 2025.

The company furnished the press release as Exhibit 99.1, which includes details about its results of operations and financial condition for the quarter, along with other financial information. The company notes that this information is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.

false 0001799191 0001799191 2025-11-13 2025-11-13 0001799191 TOI:CommonStockParValue0.0001Member 2025-11-13 2025-11-13 0001799191 TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

Form 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  November 13, 2025

___________________________________

THE ONCOLOGY INSTITUTE, INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware		001-39248		84-3562323
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

18000 Studebaker Road, Suite 800, Cerritos, CA		90703
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:  (562) 735-3226

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		TOI		The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share		TOIIW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.

Item 2.02. Results of Operations and Financial Condition

On November 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. 

The information contained in Item 2.02 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by The Oncology Institute, Inc. on November 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 13, 2025	THE ONCOLOGY INSTITUTE, INC.
	By:	/s/ Robert Carter
	Name:	Robert Carter
	Title:	Chief Financial Officer

FAQ

What did The Oncology Institute (TOI) report in this 8-K filing?

The Oncology Institute, Inc. reported that it issued a press release announcing its financial results for the three months ended September 30, 2025 and furnished that release as Exhibit 99.1.

Which period do the latest The Oncology Institute (TOI) financial results cover?

The latest financial results discussed in this filing cover the three months ended September 30, 2025.

Where can investors find the detailed Q3 2025 financial results for The Oncology Institute (TOI)?

The detailed financial results and other financial information are contained in the press release that is furnished as Exhibit 99.1 to this report.

How is the financial information in this The Oncology Institute (TOI) filing treated under the Exchange Act?

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

What exhibits are included with this The Oncology Institute (TOI) 8-K?

The filing includes Exhibit 99.1, a press release issued on November 13, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed this The Oncology Institute (TOI) 8-K report?

The report was signed on behalf of The Oncology Institute, Inc. by Robert Carter, its Chief Financial Officer.